Other equities analysts have also recently issued research reports about the stock. Societe Generale upgraded shares of DBV Technologies from a “hold” rating to a “buy” rating in a research note on Wednesday, January 4th. The Goldman Sachs Group cut shares of DBV Technologies from a “neutral” rating to a “sell” rating in a research note on Friday, December 16th. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. Based on data from MarketBeat, DBV Technologies presently has an average rating of “Hold” and a consensus target price of $5.63.
DBV Technologies Price Performance
Shares of DBV Technologies stock opened at $1.44 on Wednesday. The stock has a market cap of $271.11 million, a price-to-earnings ratio of -2.62 and a beta of 1.29. The firm’s 50-day moving average is $1.41 and its 200 day moving average is $1.83. DBV Technologies has a 1 year low of $1.08 and a 1 year high of $3.43.
Institutional Investors Weigh In On DBV Technologies
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Advisory Services Network LLC purchased a new stake in shares of DBV Technologies during the 2nd quarter valued at about $26,000. Commonwealth Equity Services LLC purchased a new stake in shares of DBV Technologies during the 3rd quarter valued at about $26,000. Two Sigma Investments LP increased its holdings in DBV Technologies by 80.9% in the 3rd quarter. Two Sigma Investments LP now owns 35,920 shares of the company’s stock worth $64,000 after acquiring an additional 16,066 shares in the last quarter. BNP Paribas Arbitrage SA purchased a new stake in DBV Technologies in the 2nd quarter worth approximately $49,000. Finally, Optiver Holding B.V. purchased a new stake in DBV Technologies in the 3rd quarter worth approximately $36,000. Hedge funds and other institutional investors own 18.37% of the company’s stock.
DBV Technologies Company Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults.
- Get a free copy of the StockNews.com research report on DBV Technologies (DBVT)
- 3 Retail Stocks Ringing the Register in 2023
- Is It Time To Get Aggressive With Defense Stocks?
- When Will Crane Holdings Take Flight?
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.